首页> 外文期刊>BMC Infectious Diseases >Universal test, treat, and keep: improving ART retention is key in cost-effective HIV control in Uganda
【24h】

Universal test, treat, and keep: improving ART retention is key in cost-effective HIV control in Uganda

机译:通用测试,治疗和保留:提高抗病毒治疗的保留率是乌干达经济高效地控制艾滋病毒的关键

获取原文
           

摘要

Background With ambitious new UNAIDS targets to end AIDS by 2030, and new WHO treatment guidelines, there is increased interest in the best way to scale-up ART coverage. We investigate the cost-effectiveness of various ART scale-up options in Uganda. Methods Individual-based HIV/ART model of Uganda, calibrated using history matching. 22 ART scale-up strategies were simulated from 2016 to 2030, comprising different combinations of six single interventions (1. increased HIV testing rates, 2. no CD4 threshold for ART initiation, 3. improved ART retention, 4. increased ART restart rates, 5. improved linkage to care, 6. improved pre-ART care). The incremental net monetary benefit (NMB) of each intervention was calculated, for a wide range of different willingness/ability to pay (WTP) per DALY averted (health-service perspective, 3% discount rate). Results For all WTP thresholds above $210, interventions including removing the CD4 threshold were likely to be most cost-effective. At a WTP of $715 (1?×?per-capita-GDP) interventions to improve linkage to and retention/re-enrolment in HIV care were highly likely to be more cost-effective than interventions to increase rates of HIV testing. At higher WTP (>?~?$1690), the most cost-effective option was ‘Universal Test, Treat, and Keep’ (UTTK), which combines interventions 1–5 detailed above. Conclusions Our results support new WHO guidelines to remove the CD4 threshold for ART initiation in Uganda. With additional resources, this could be supplemented with interventions aimed at improving linkage to and/or retention in HIV care. To achieve the greatest reductions in HIV incidence, a UTTK policy should be implemented.
机译:背景技术随着联合国艾滋病规划署新的雄心勃勃的新目标,即到2030年终结艾滋病,以及世卫组织制定了新的治疗指南,人们对扩大抗逆转录病毒疗法覆盖率的最佳途径的兴趣日益浓厚。我们调查了乌干达各种ART扩大方案的成本效益。方法乌干达基于个人的HIV / ART模型,使用历史匹配进行校准。从2016年到2030年,我们模拟了22种抗逆转录病毒疗法的扩大策略,包括六种单一干预措施的不同组合(1.提高艾滋病毒检测率; 2。抗病毒治疗的CD4阈值没有提高; 3。抗病毒治疗的保留率提高; 4。抗病毒治疗的重新启动率增加; 5.改善与护理之间的联系,6.改善ART之前的护理)。针对每项避免的残疾调整生命年的各种不同的支付意愿/支付能力(WTP),计算了每种干预措施的增量净货币收益(NMB)(从卫生服务角度,折现率为3%)。结果对于所有高于210美元的WTP阈值,包括删除CD4阈值在内的干预措施可能是最具成本效益的。以715美元(人均GDP的1×x?)的WTP而言,与提高HIV检测率的干预措施相比,改善与HIV护理的联系以及保留/重新注册的干预措施更具成本效益。在更高的WTP(>?〜?$ 1690)时,最具成本效益的选择是“通用测试,治疗和保留”(UTTK),该方法结合了上面详述的干预1-5。结论我们的结果支持新的WHO指南,以消除乌干达开始抗病毒治疗的CD4阈值。有了额外的资源,可以辅之以旨在改善与艾滋病毒护理的联系和/或保留的干预措施。为了最大程度地减少艾滋病毒的发病率,应实施UTTK政策。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号